To acquire Protech Manufacturing and Packaging for $400,000 and 50,000 shares of Trimfast stock, the company announces Feb. 17. Tampa, Fla.-based Trimfast markets supplement products including TrimFast Herbal Plus, Immune Blast, Max Imact, Sudden Energy, Ginseng Zing, HumaTropin AM, HumaTropin PM and MyoBlast as well as Kicks childrens multivitamin. Protech manufactures dietary supplement and food products. Under the terms of the proposed deal, Protech will be a subsidiary of TrimFast, manufacturing products sold by the TrimFast Inc. and Body Life Sciences Inc. subsidiaries, "as well as manufacturing other products for its own accounts." Trimfast is one of several firms that voluntarily recalled their GBL products in response to a request by FDA ("The Tan Sheet" Feb. 1, p. 3)
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.
The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.
